Diabetologia:2型糖尿病女性患者的卒中风险随HbA1c水平的增高而上升

2014-03-06 佚名 睿医资讯

一项大规模前瞻性研究显示,2型糖尿病女性患者的卒中风险随之HbA1c水平的增高而呈现上升趋势。血糖控制不佳对于55岁以上糖尿病女性患者的卒中发生影响最大。 为明确血糖控制与卒中间的相关性,研究者们以路易斯安那州立大学医院为背景进行了一项纵向研究(LSUHLS),相关结果2月24日在线发表于Diabetologia杂志。 这项研究指出,糖尿病与卒中风险的相关性,在

一项大规模前瞻性研究显示,2型糖尿病女性患者的卒中风险随之HbA1c水平的增高而呈现上升趋势。血糖控制不佳对于55岁以上糖尿病女性患者的卒中发生影响最大。

为明确血糖控制与卒中间的相关性,研究者们以路易斯安那州立大学医院为背景进行了一项纵向研究(LSUHLS),相关结果2月24日在线发表于Diabetologia杂志。

这项研究指出,糖尿病与卒中风险的相关性,在女性患者中更加明显。

研究主要结果表明,在接受了为期6.7年的随访后,在10 876例男性和19 278例女性2型糖尿病患者中,发生卒中的分别有1093例和1856例。女性患者中HbA1c水平增高与卒中风险间存在显著相关性,而该相关性在男性患者中并不存在。

对多变量进行校准后可见,HbA1c在8.0-8.9%范围内的女性患者,其发生卒中的可能性比血糖水平正常者更高;HbA1c在9.0-9.9%范围内的女性患者,卒中风险增高32%;HbA1c高于10%的女性患者,其卒中风险增高42%(P< .001)。男性患者中虽然也有类似趋势,但并不具有统计学意义。

HbA1c与卒中风险间的相关性具有性别差异,这也许提示男女患者的治疗方案应有所区别。

原始出处:

Becky McCall.Stroke Risk Increases With HbA1c Level in Women but Not Men.Medscape March 03, 2014

Zhao W1, Katzmarzyk PT, Horswell R, Wang Y, Johnson J, Hu G.Sex differences in the risk of stroke and HbA1c among diabetic patients.Diabetologia. 2014 Feb 28.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2033481, encodeId=615b20334811c, content=<a href='/topic/show?id=446044648ad' target=_blank style='color:#2F92EE;'>#女性患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44648, encryptionId=446044648ad, topicName=女性患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Tue Jan 20 21:05:00 CST 2015, time=2015-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2015891, encodeId=d1a620158911d, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Nov 01 17:05:00 CST 2014, time=2014-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759416, encodeId=70861e59416d6, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Dec 30 21:05:00 CST 2014, time=2014-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636829, encodeId=6336163682976, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Nov 01 22:05:00 CST 2014, time=2014-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281165, encodeId=6901128116533, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Sat Mar 08 00:05:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561557, encodeId=4ad1156155e20, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Mar 08 00:05:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567566, encodeId=694a156e56618, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Mar 08 00:05:00 CST 2014, time=2014-03-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2033481, encodeId=615b20334811c, content=<a href='/topic/show?id=446044648ad' target=_blank style='color:#2F92EE;'>#女性患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44648, encryptionId=446044648ad, topicName=女性患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Tue Jan 20 21:05:00 CST 2015, time=2015-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2015891, encodeId=d1a620158911d, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Nov 01 17:05:00 CST 2014, time=2014-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759416, encodeId=70861e59416d6, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Dec 30 21:05:00 CST 2014, time=2014-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636829, encodeId=6336163682976, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Nov 01 22:05:00 CST 2014, time=2014-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281165, encodeId=6901128116533, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Sat Mar 08 00:05:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561557, encodeId=4ad1156155e20, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Mar 08 00:05:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567566, encodeId=694a156e56618, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Mar 08 00:05:00 CST 2014, time=2014-03-08, status=1, ipAttribution=)]
    2014-11-01 Smile2680
  3. [GetPortalCommentsPageByObjectIdResponse(id=2033481, encodeId=615b20334811c, content=<a href='/topic/show?id=446044648ad' target=_blank style='color:#2F92EE;'>#女性患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44648, encryptionId=446044648ad, topicName=女性患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Tue Jan 20 21:05:00 CST 2015, time=2015-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2015891, encodeId=d1a620158911d, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Nov 01 17:05:00 CST 2014, time=2014-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759416, encodeId=70861e59416d6, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Dec 30 21:05:00 CST 2014, time=2014-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636829, encodeId=6336163682976, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Nov 01 22:05:00 CST 2014, time=2014-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281165, encodeId=6901128116533, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Sat Mar 08 00:05:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561557, encodeId=4ad1156155e20, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Mar 08 00:05:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567566, encodeId=694a156e56618, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Mar 08 00:05:00 CST 2014, time=2014-03-08, status=1, ipAttribution=)]
    2014-12-30 智智灵药
  4. [GetPortalCommentsPageByObjectIdResponse(id=2033481, encodeId=615b20334811c, content=<a href='/topic/show?id=446044648ad' target=_blank style='color:#2F92EE;'>#女性患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44648, encryptionId=446044648ad, topicName=女性患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Tue Jan 20 21:05:00 CST 2015, time=2015-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2015891, encodeId=d1a620158911d, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Nov 01 17:05:00 CST 2014, time=2014-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759416, encodeId=70861e59416d6, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Dec 30 21:05:00 CST 2014, time=2014-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636829, encodeId=6336163682976, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Nov 01 22:05:00 CST 2014, time=2014-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281165, encodeId=6901128116533, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Sat Mar 08 00:05:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561557, encodeId=4ad1156155e20, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Mar 08 00:05:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567566, encodeId=694a156e56618, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Mar 08 00:05:00 CST 2014, time=2014-03-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2033481, encodeId=615b20334811c, content=<a href='/topic/show?id=446044648ad' target=_blank style='color:#2F92EE;'>#女性患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44648, encryptionId=446044648ad, topicName=女性患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Tue Jan 20 21:05:00 CST 2015, time=2015-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2015891, encodeId=d1a620158911d, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Nov 01 17:05:00 CST 2014, time=2014-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759416, encodeId=70861e59416d6, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Dec 30 21:05:00 CST 2014, time=2014-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636829, encodeId=6336163682976, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Nov 01 22:05:00 CST 2014, time=2014-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281165, encodeId=6901128116533, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Sat Mar 08 00:05:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561557, encodeId=4ad1156155e20, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Mar 08 00:05:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567566, encodeId=694a156e56618, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Mar 08 00:05:00 CST 2014, time=2014-03-08, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2033481, encodeId=615b20334811c, content=<a href='/topic/show?id=446044648ad' target=_blank style='color:#2F92EE;'>#女性患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44648, encryptionId=446044648ad, topicName=女性患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Tue Jan 20 21:05:00 CST 2015, time=2015-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2015891, encodeId=d1a620158911d, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Nov 01 17:05:00 CST 2014, time=2014-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759416, encodeId=70861e59416d6, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Dec 30 21:05:00 CST 2014, time=2014-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636829, encodeId=6336163682976, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Nov 01 22:05:00 CST 2014, time=2014-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281165, encodeId=6901128116533, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Sat Mar 08 00:05:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561557, encodeId=4ad1156155e20, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Mar 08 00:05:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567566, encodeId=694a156e56618, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Mar 08 00:05:00 CST 2014, time=2014-03-08, status=1, ipAttribution=)]
    2014-03-08 liuxiaona
  7. [GetPortalCommentsPageByObjectIdResponse(id=2033481, encodeId=615b20334811c, content=<a href='/topic/show?id=446044648ad' target=_blank style='color:#2F92EE;'>#女性患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44648, encryptionId=446044648ad, topicName=女性患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e0a1165, createdName=jiangfeng5067, createdTime=Tue Jan 20 21:05:00 CST 2015, time=2015-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2015891, encodeId=d1a620158911d, content=<a href='/topic/show?id=33108494c1' target=_blank style='color:#2F92EE;'>#HbA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8494, encryptionId=33108494c1, topicName=HbA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Sat Nov 01 17:05:00 CST 2014, time=2014-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759416, encodeId=70861e59416d6, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Dec 30 21:05:00 CST 2014, time=2014-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1636829, encodeId=6336163682976, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Nov 01 22:05:00 CST 2014, time=2014-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1281165, encodeId=6901128116533, content=<a href='/topic/show?id=455f36085f0' target=_blank style='color:#2F92EE;'>#卒中风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36085, encryptionId=455f36085f0, topicName=卒中风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8f1167, createdName=wmr111, createdTime=Sat Mar 08 00:05:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561557, encodeId=4ad1156155e20, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Mar 08 00:05:00 CST 2014, time=2014-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1567566, encodeId=694a156e56618, content=<a href='/topic/show?id=118142341b1' target=_blank style='color:#2F92EE;'>#增高#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42341, encryptionId=118142341b1, topicName=增高)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=af9415191444, createdName=liuxiaona, createdTime=Sat Mar 08 00:05:00 CST 2014, time=2014-03-08, status=1, ipAttribution=)]
    2014-03-08 liuxiaona

相关资讯

EMA推荐糖尿病新药Vokanamet(SGLT-2阻断剂)上市

2月20日,欧洲药品管理局(EMA)人用医药产品委员会(CHMP)推荐糖尿病治疗药物Vokanamet(活性成分为Canagliflozin和二甲双胍)授权上市。 Vokanamet适用于最大耐受剂量二甲双胍仍无法充分控制血糖水平的成人2型糖尿病患者,最大耐受剂量二甲双胍与包括胰岛素在内的其他降糖药联用仍无法充分控制血糖者,以及canagliflozin和二甲双胍单独片剂疗效不佳者。 Voka

JAMA:早产儿与成年后2型糖尿病密切相关

肥胖、糖尿病、心血管疾病及肿瘤统称为非传染性疾病(noncommunicable diseases,NCDs),其关注重点主要集中在疾病的预防和控制,是发达国家,更是发展中国家面临的重大挑战。 发展中国家城市化进程和经济的加速,导致长时间久坐、不健康饮食、吸烟、应激行为的发生,暴露于环境污染的几率也随之增加。NCDs总体发病率高,在年轻人群中呈上升趋势。因为疾病产生的治疗费用,导致的

中国高血糖危象诊断与治疗指南

近30年来我国糖尿病患病率显著升高,最近10年糖尿病流行情况更为严重。2007至2008年中华医学会糖尿病学分会组织全国14个省(市)进行了糖尿病流行病学调查,结果显示我国20岁以上成人糖尿病患病率为9.7%,中国成人糖尿病总数达9240万,我国目前可能已成为糖尿病患病人数最多的国家。更令人担忧的是,这次调查还发现60.0%的糖尿病患者未得到及时诊断,这些患者存在很大风险,尤以高血糖危象为首发症状

沃森:糖尿病可能是因为的“氧化不足”导致

    DNA双螺旋结构的发现者,诺贝尔奖得主James D. Watson于二月二十七日在著名医学杂志《柳叶刀》上提出了二型糖尿病发病机制的新假说。他的这一理论将作为《柳叶刀》的封面文章刊发。    Watson指出,糖尿病、痴呆、心血管疾病和一些癌症都与生物学氧化剂(活性氧ROS)生成不足的有关。他还强调,更好的理解体育锻炼的作用

Lancet:“DNA之父”提出颠覆性糖尿病理论

DNA双螺旋结构的发现者,诺贝尔奖得主James D. Watson于二月二十七日在着名医学杂志《柳叶刀》上提出了二型糖尿病发病机制的新假说。他的这一理论将作为《柳叶刀》的封面文章刊发。Watson指出,糖尿病、痴呆、心血管疾病和一些癌症都与生物学氧化剂(活性氧ROS)生成不足的有关。他还强调,更好的理解体育锻炼的作用,可以帮助人们治疗上述疾病。“如今人们普遍认为二型糖尿病的发病原因是,”Dr.

谌贻璞:对2型糖尿病患者中CKD的高患病率应予高度重视

近十余年,国内已发表了几篇有关2型糖尿病(T2DM)患者慢性肾脏病(CKD)患病率的流调报告。2002年,中华医学会糖尿病学分会发表了 全国住院糖尿病患者慢性并发症的调查报告,其中并发临床肾脏病(包括慢性肾功能不全及尿毒症)者占33.6%;2008年上海复旦大学发表了他们组织的上海市市区30岁以上T2DM患者的流调报告,CKD患病率高达63.9%;而2012年江苏省老年病研